Clinical Trials Browser

Phase 1/2 × INDUSTRY × Neurofibroma, Plexiform × Clear all

NCT07024394 2025-06-17

Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1

Phase 1/2 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04954001 2024-11-12

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Phase 1/2 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02124772 2021-07-14

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Phase 1/2 Completed

139 enrolled 42 charts 1 FDA

Histiocytosis, Langerhans-Cell, Neoplasms, Neuroblastoma, Neurofibroma, Plexiform